Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Dow
Baxter
Harvard Business School
Boehringer Ingelheim

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for BCT197

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug BCT197?

BCT197 is an investigational drug.

There have been 5 clinical trials for BCT197. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2011.

The most common disease conditions in clinical trials are Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive, and Lung Diseases. The leading clinical trial sponsors are Mereo BioPharma, Novartis Pharmaceuticals, and [disabled in preview].

There are six US patents protecting this investigational drug and one hundred and six international patents.

Recent Clinical Trials for BCT197
TitleSponsorPhase
The Effect of Itraconazole on BCT197 Exposure in Healthy Male ParticipantsMereo BioPharmaPhase 1
The Effect of Azithromycin on BCT197 Exposure in Healthy Male VolunteersMereo BioPharmaPhase 1
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary DiseaseMereo BioPharmaPhase 2

See all BCT197 clinical trials

Clinical Trial Summary for BCT197

Top disease conditions for BCT197
Top clinical trial sponsors for BCT197

See all BCT197 clinical trials

US Patents for BCT197

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BCT197   Start Trial 5-membered heterocycle-based p38 kinase inhibitors Novartis AG (Basel, CH)   Start Trial
BCT197   Start Trial 5-membered heterocycle-based p38 kinase inhibitors Novartis AG (Basel, CH)   Start Trial
BCT197   Start Trial 5-membered heterocycle-based P38 kinase inhibitors Novartis AG (Basel, CH)   Start Trial
BCT197   Start Trial 5-membered heterocycle-based p38 kinase inhibitors Novartis AG (Basel, CH)   Start Trial
BCT197   Start Trial Method of treating contrast-induced nephropathy Novartis AG (Basel, CH)   Start Trial
BCT197   Start Trial Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease Mereo BioPharma 1 Limited (London, GB)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for BCT197

Drugname Country Document Number Estimated Expiration Related US Patent
BCT197 Austria 517872 2023-06-26   Start Trial
BCT197 Australia 2004259662 2023-06-26   Start Trial
BCT197 Brazil PI0411825 2023-06-26   Start Trial
BCT197 Canada 2526455 2023-06-26   Start Trial
BCT197 China 1832928 2023-06-26   Start Trial
BCT197 Cyprus 1111985 2023-06-26   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Express Scripts
Colorcon
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.